Home

Gregory A Gould

CIK 1252905 · CFO · last filed 2026-08-18

Gregory A Gould is a CFO who has filed 55 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider bought $24.5K of ACON on Aug 18, 2026. Across all open-market trades the lifetime net is +$24.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $157.3K across reported positions. 3 SEC filings were submitted jointly with Ampio Pharmaceuticals, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$157.3K

Companies

5

Total Filings

55

Lifetime Open-Market Net

$24.5K

Filer Profile

Reported Address
8181 ARISTA PLACE
SUITE 100
BROOMFIELD, CO 80021
Related Filers
Ampio Pharmaceuticals, Inc. — 3 joint filings, latest 2016-07-19
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACON CFO 60,000 $2.60 $156.0K $24.5K 1 2026-08-18
ACONW Chief Financial Officer 50,000 $0.03 $1.3K $0 2 2026-06-12
NewAge, Inc. (NBEV) Delisted Chief Financial Officer 331,255 $0.09 $31.0K $0 7 2021-07-07
Ampio Pharmaceuticals, Inc. (AMPE) Delisted Chief Financial Officer — $0.18 — $0 2 2016-07-19
SERACARE LIFE SCIENCES INC (SRLS) Delisted Interim CEO, CFO, Treas & Sec. 0 — — $0 17 2012-04-20

Recent Filings

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-18 ACON Buy (P) +10,000 $24.5K EDGAR
2026-06-12 ACONW Grant (A) +50,000 $0 EDGAR
2025-09-03 ACONW Grant (A) — $0 EDGAR
2022-06-21 — Grant (A) — $0
2021-07-07 NewAge, Inc. (NBEV) Delisted Tax (F) −73,110 -$163.8K EDGAR
2021-03-12 NewAge, Inc. (NBEV) Delisted Grant (A) — $0 EDGAR
2021-01-05 NewAge, Inc. (NBEV) Delisted Tax (F) −26,507 -$69.7K EDGAR
2020-12-11 NewAge, Inc. (NBEV) Delisted Tax (F) −9,564 -$30.2K EDGAR
2020-10-26 NewAge, Inc. (NBEV) Delisted Tax (F) −9,564 -$26.0K EDGAR
2019-12-12 NewAge, Inc. (NBEV) Delisted Grant (A) +100,000 $0 EDGAR
Showing 1–10 of 55
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.